CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Topiramatedrug
Likely dose
Topiramate 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00300742
NCT00300742Phase 2Completed
CompareCT.gov

Topiramate for the Treatment of Alcohol Dependent Binge-Eating Disordered Individual

University of Virginia·interventional·Posted Mar 9, 2006·Updated Jul 12, 2017

In Brief

A Phase 2 clinical trial evaluating Topiramate for Alcohol Dependence and Binge Eating. Completed, enrolled 5 participants across 2 sites.

Detailed Summary

The purpose of this study is to test the feasibility of using topiramate to reduce binge eating and drinking episodes in alcohol dependent individuals with comorbid binge eating disorder.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Dependence, Binge Eating
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 9, 2006
Enrollment StartMar 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 20.3 years ago

Interventions

Topiramatedrug

Topiramate up to 300 mg per day.